Moreover, studies on serum NfL levels in individuals with CIS and MS showed that not only serum NfL levels are associated with the activity of the disease, patient response to DMT, and the long-term outcomes but also that serum NfL levels represent an independent factor of relapse in CIS and early MS individuals [85,86,87,88]. This evidence concerns the gene NEFL and in situ carcinoma.